title: The treatment of hyponatraemia using vasopressin antagonists.
abstract: Hyponatraemia is a frequent electrolyte disorder. It is primarily attributable to vasopressin excess plus sustained fluid intake. Hyponatraemia causes CNS symptoms, especially during the first 2-4 days; these symptoms are related to brain swelling. Hyponatraemia occurs in the setting of liver cirrhosis and congestive cardiac failure, in which it is related to stimulation by low arterial blood pressure acting through baroreceptors. Hyponatraemia also occurs in the syndrome of inappropriate antidiuretic hormone secretion, usually from neoplasms releasing vasopressin. The conventional treatment of hyponatraemia used to be fluid restriction and treatment of the underlying disorder. This kind of treatment has been unreliable, cumbersome and difficult to comply with for the patient. In the future, effective vasopressin V2 antagonists will become available for clinical use in the treatment of hyponatraemia, and are expected to improve the management of hyponatraemia. Pharmacological characteristics and observations of biological effects of three antagonists are reported in the present article.
authors.affiliation: Department of Medicine, Universitätsklinikum C.G. Carus, Dresden, Germany. peter.gross@mailbox.tu-dresden.de
authors.forename: P
authors.initials: P
authors.lastname: Gross
authors.forename: C
authors.initials: C
authors.lastname: Palm
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001381:Azepines / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D009025:Morpholines / Q000627:therapeutic use; D011758:Pyrroles; D017483:Receptors, Vasopressin / Q000378:metabolism; D013141:Spiro Compounds / Q000627:therapeutic use; D014667:Vasopressins / Q000037:antagonists & inhibitors* / Q000097:blood; D001569:Benzodiazepines
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001381:Azepines; D001549:Benzamides; D001552:Benzazepines; D009025:Morpholines; D011758:Pyrroles; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; D014667:Vasopressins; C076251:mozavaptan; C409452:lixivaptan; D001569:Benzodiazepines; C103281:satavaptan